Capital Markets Day, May 22

We invite you to participate in our Capital Markets Day for a look into Fluicell’s development and future our strategies. The Capital Markets Day will be held digitally on 22 May at 13.30-15.30 CEST. Fluicell will provide an update on the Company’s development work and growth strategy and provide an insight into Fluicell’s progress in regenerative medicine and tissue-based disease models.

CEO Victoire Viannay comments:

Fluicell is in an incredibly exciting phase right now where we have a unique opportunity to create groundbreaking solutions in regenerative medicine and drug development, based on our role as an innovation leader in bioprinting and tissue engineering. Today, we are well on our way to meeting many of our ambitious development goals and are now laying the foundation for our future growth.

Building on the strengthened market position for our research solutions, our partnership on bioprinted cardiac safety models and our development program for bioprinted tissue therapeutics for the treatment of type 1 diabetes, we are building a Fluicell that is changing the way diseases are treated. I am very pleased to welcome investors to our Capital Markets Day on May 22 to learn about our ongoing progress and plans for Fluicell’s future development.

The Capital Markets Day will be held digitally and will be broadcast live with the opportunity for participants to ask questions. Please use the following link to participate on May 22 or ask the Company questions in advance:

For those who do not have the opportunity to follow the live broadcast directly, a recorded version will be available afterwards on our website.